Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating HLX79 in combination with Rituximab versus placebo for active glomerulonephritis, including membranous nephropathy and lupus nephritis,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Membranous Nephropathy

Drugs mentioned

• HLX79 (human sialidase fusion protein)
• Rituximab (rituximab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Membranous Nephropathy, Lupus Nephritis (LN) | Phase 2 | Status: RECRUITING